Anti-SARS-COV2 Vaccination Study in Lung Cancer Patients
NCT ID: NCT05009030
Last Updated: 2022-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
794 participants
OBSERVATIONAL
2021-05-06
2022-03-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aims to be nationwide in order to study general common variables of the patients, as well as the correlation with the cancer treatments received.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection
NCT04407143
Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC
NCT05641870
Impact of Confinement and Preventive Measures in Period of SARS-COV2 Infection on Clinical Features, Diagnostic and Therapeutic Management and Prognosis of Patients With Lung Cancer
NCT04366219
Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment
NCT05382052
LunG and Melanoma canceR pAtients coVId19 Disease (GRAVID)
NCT04344002
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study aims to be nationwide in order to study general common variables of the patients, as well as the correlation with the cancer treatments received.
Disease and study population Patients with lung cancer of any histology and stage who receive an anti-COVID-19 vaccine approved by the health authorities. Patients would be eligible whether they have suffered from SARS-CoV2 infection or have not had COVID19.
The study will be extended to all the centers of the Spanish Lung Cancer Group, more than 170 centers and 500 professionals, and it is expected that around 500 cases will be collected.
The main objective of the study is to collect the safety and efficacy of the vaccine against SARS-CoV-2 in cancer patients, as well as its potential interactions with antineoplastic therapies.
The data collection will take place throughout the year 2021
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study group
Patients with lung cancer of any histology and stage who receive an anti-COVID-19 vaccine approved by the health authorities. Patients would be eligible whether they have suffered from SARS-CoV2 infection or have not had COVID19.
COVID-19 vaccine
Lung cancer patients will receive an anti-COVID19 vaccine approved by the European Medicines Agency according to the guidelines approved by the regulatory authorities
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COVID-19 vaccine
Lung cancer patients will receive an anti-COVID19 vaccine approved by the European Medicines Agency according to the guidelines approved by the regulatory authorities
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age equal to or greater than 18 years
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundación GECP
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ernest Nadal, MD
Role: STUDY_CHAIR
Fundación GECP Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Complejo Hospitalario Universitario De Santiago
Santiago de Compostela, A Coruña, Spain
Hospital General Universitario de Elche
Elche, Alicante, Spain
Hospital De Torrevieja
Torrevieja, Alicante, Spain
Hospital Universitario Araba-Sede Txagorritxu
Vitoria-Gasteiz, Araba, Spain
Hospital Germans Trias I Pujol
Badalona, Barcelona, Spain
ICO Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital De Mataro
Mataró, Barcelona, Spain
Hospital Galdakao-Usansolo
Galdakao, Bizkaia, Spain
Hospital La Mancha Centro
Alcázar de San Juan, Ciudad Real, Spain
Hospital Universitario Jerez De La Frontera
Jerez de la Frontera, Cádiz, Spain
Hospital Universitario Insular de Gran canaria
Las Palmas de Gran Canaria, Gran Canaria, Spain
Hospital San Pedro De Logroño
Logroño, La Rioja, Spain
Hospital Universitario Severo Ochoa
Leganés, Madrid, Spain
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, Spain
Hospital Universitario De Mostoles
Móstoles, Madrid, Spain
Hospital Universitario Quiron Madrid
Pozuelo de Alarcón, Madrid, Spain
Hospital Verge De La Cinta
Tortosa, Tarragona, Spain
Hospital Universitario Cruces
Barakaldo, Vizcaya, Spain
Hospital Universitario De A Coruna
A Coruña, , Spain
Hospital General Universitario de Alicante
Alicante, , Spain
Hospital Nuestra Señora De Sonsoles
Ávila, , Spain
Hospital Universitari Quiron Dexeus
Barcelona, , Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Hospital de Basurto
Bilbao, , Spain
ICO Girona, Hospital Josep Trueta
Girona, , Spain
Hospital Universitario Virgen De Las Nieves
Granada, , Spain
Hospital San Cecilio
Granada, , Spain
Hospital Universitario de Jaén
Jaén, , Spain
Hospital Universitario de León
León, , Spain
Hospital Universitario Lucus Augusti
Lugo, , Spain
Hospital Universitario Infanta Leonor
Madrid, , Spain
Hospital Clínico San Carlos
Madrid, , Spain
Hospital 12 De Octubre
Madrid, , Spain
Hospital Universitario HM Sanchinarro
Madrid, , Spain
Hospital Fundación de Alcorcón
Madrid, , Spain
Hospital General Universitario de Málaga
Málaga, , Spain
Hospital Universitari Son Llatzer
Palma de Mallorca, , Spain
Complejo Hospitalario Pontevedra
Pontevedra, , Spain
Hospital Clínico de Salamanca
Salamanca, , Spain
Hospital Universitario Nuestra Señora La Candelaria
Santa Cruz de Tenerife, , Spain
Hospital General De Segovia
Segovia, , Spain
Hospital De Valme
Seville, , Spain
Hospital De Sant Pau i Sta. Tecla
Tarragona, , Spain
Hospital Virgen De La Salud
Toledo, , Spain
Instituto Valenciano De Oncología
Valencia, , Spain
Hospital General Universitario de Valencia
Valencia, , Spain
Hospital Universitario Dr. Peset
Valencia, , Spain
Hospital Universitario La Fe
Valencia, , Spain
Hospital Clínico Universitario de Valladolid
Valladolid, , Spain
Complejo Asistencial De Zamora
Zamora, , Spain
Hospital Miguel Servet
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Web page of the sponsor where users can find more information about Fundación GECP studies
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GECP 21/01_VAC-CaP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.